First experience with MRI-guided vacuum aspirated breast biopsy

2020 ◽  
pp. 25-31
Author(s):  
M. L. Mazo ◽  
O. E. Jacobs ◽  
O. S. Puchkova ◽  
M. V. Feldsherov ◽  
E. V. Kondratyev
Keyword(s):  
Breast Cancer ◽  
Breast Augmentation ◽  
Breast Biopsy ◽  
Breast Mri ◽  
Breast Tumors ◽  
High Tech ◽  
X Ray ◽  
Vacuum Aspiration ◽  
Mri Guided ◽  
Aesthetic Breast

The rate of detection of breast cancer by MRI, while other methods of radiological diagnosis are not sufficiently informative, ranges from 5.2 to 26.3 per cent. Suspicious breast tumors of category BI-RADS 4, 5 show morphological image-guided biopsy verification, in particular MRI with contrast. Purpose. To show the possibilities and features of carrying out MRI-guided vacuum breast biopsy, including after aesthetic breast augmentation. Material and methods. A comprehensive X-ray, ultrasound and MRI examination of 54 women aged between 28 and 70 years with different breast tumors was conducted. Of these, five were detected only by breast MRI with contrast, and were morphologically verified by MRI-guided vacuum aspiration biopsy. Results. 14 of the 54 patients with breast mass were diagnosed with breast cancer and 26 were diagnosed with benign diseases. The effectiveness of comprehensive examination and low-invasive high-tech MRI-guided procedures in early refined screening for breast cancer, including after aesthetic breast augmentation, has been demonstrated. MRI-guided vacuum-assisted breast biopsy is a fast, safe and accurate diagnostic method of morphological verification of suspicious breast tumors that do not have X-ray and ultrasound.

scholarly journals Enhanced MRI and MRI-Guided Interventional Procedures in Women with Asymptomatic Silicone-Injected Breasts

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Yun-Chung Cheung ◽  
Shin-Chih Chen ◽  
Yung-Feng Lo
Keyword(s):  
Breast Cancer ◽  
Breast Augmentation ◽  
Interventional Procedures ◽  
Breast Mri ◽  
Silicone Injection ◽  
Enhanced Mri ◽  
Breast Sonography ◽  
Mri Guided ◽  
Asymptomatic Women ◽  
Suspicious Lesions

Asymptomatic women who have received silicone injection for breast augmentation have a risk of underestimating breast cancer by palpation, mammography, or breast sonography. Enhanced breast MRI is sensitive to display certain nonspecific enhanced lesions or suspicious lesions. Such nonspecific MRI-detected lesions could be managed by American College Radiology BI-RADS lexicon and selectively with MRI-guided techniques biopsy to prevent unnecessary surgery.

scholarly journals Aesthetic breast augmentation with hyaluronic acid: imaging findings and implications for radiological assessment

2012 ◽  
Vol 45 (3) ◽  
pp. 181-183 ◽  
Author(s):  
Divanei Aparecida Bottaro Criado ◽  
Fernanda Del Campo Braojos ◽  
Ulysses dos Santos Torres ◽  
Marcos Pontes Muniz
Keyword(s):  
Breast Cancer ◽  
Hyaluronic Acid ◽  
Breast Augmentation ◽  
Radiological Assessment ◽  
Radiological Evaluation ◽  
Imaging Findings ◽  
Injectable Fillers ◽  
Aesthetic Breast

New injectable fillers such as hyaluronic acid have recently been employed as a non-surgical alternative to implants such as silicone for aesthetic breast enhancement. Although their utilization is not yet widespread in Brazil, radiologists should be aware of the imaging findings in this context and of the implications of the presence of this filler for the radiological evaluation in the screening for breast cancer.

scholarly journals Pure Fibrocystic Change Diagnosed at MRI-guided Vacuum-assisted Breast Biopsy: Imaging Features and Follow-up Outcomes

2020 ◽  
Vol 2 (2) ◽  
pp. 141-146
Author(s):  
Shu-Tian Chen ◽  
Satoko Okamoto ◽  
Bruce L Daniel ◽  
James Covelli ◽  
Wendy B DeMartini ◽  
...  
Keyword(s):  
Breast Biopsy ◽  
Breast Mri ◽  
Lesion Size ◽  
Imaging Features ◽  
Mri Features ◽  
Fibrocystic Change ◽  
Mri Guided ◽  
Lesion Regression ◽  
Mri Characteristics

Abstract Objective Fibrocystic change (FCC) is considered one of the most common benign findings in the breast and may be commonly seen on breast MRI. We performed this study to identify MRI characteristics of pure FCC on MRI-guided vacuum-assisted breast biopsy (VABB) without other associated pathologies and describe the findings on MRI follow-up and outcomes. Methods A retrospective review was performed for 598 lesions undergoing 9-gauge MRI-guided VABB at our institution from January 2015 to April 2018, identifying 49 pure FCC lesions in 43 patients. The associations between variables and lesion changes on follow-up MRI were analyzed using exact Mann-Whitney tests and Fisher’s exact tests. Results MRI features of pure FCC are predominantly clumped nonmass enhancement (19/49, 39%) or irregular masses with initial fast/late washout kinetics (9/49, 18%). There was no upgrade to high-risk or cancerous lesions among the 11 patients (25.6%) who underwent surgery. There were 22 pure FCC lesions in 19 (44.2%) patients who had follow-up MRI (mean 18.0 months, range 11–41 months) showing regression (13, 59%), stability (8, 36%), or progression (1, 5%) of the lesion size, and no cancers were found on follow-up at the site of the MRI biopsy for fibrocystic changes. No patient demographics or lesion features were associated with lesion regression or stability (P > 0.05). Conclusion Our study shows that MRI features of VABB-proven FCC lesions may mimic malignancy. After VABB of pure FCC, given that adequate sampling has been performed, a 12-month follow-up MRI may be reasonable.

scholarly journals Pathologic Findings in MRI-Guided Needle Core Biopsies of the Breast in Patients with Newly Diagnosed Breast Cancer

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
K. P. Siziopikou ◽  
P. Jokich ◽  
M. Cobleigh
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Early Stage ◽  
Benign Lesion ◽  
Breast Mri ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Mri Findings ◽  
Mri Guided ◽  
New Diagnosis

The role of MRI in the management of breast carcinoma is rapidly evolving from its initial use for specific indications only to a more widespread use on all women with newly diagnosed early stage breast cancer. However, there are many concerns that such widespread use is premature since detailed correlation of MRI findings with the underlying histopathology of the breast lesions is still evolving and clear evidence for improvements in management and overall prognosis of breast cancer patients evaluated by breast MRI after their initial cancer diagnosis is lacking. In this paper, we would like to bring attention to a benign lesion that is frequently present on MRI-guided breast biopsies performed on suspicious MRI findings in the affected breast of patients with a new diagnosis of breast carcinoma.

Contrast enhanced spectral mammography (CESM) guided breast biopsy as an alternative to MRI guided biopsy

2022 ◽  
Author(s):  
Jonathan James
Keyword(s):  
Breast Biopsy ◽  
Lobular Carcinoma ◽  
Breast Mri ◽  
Diagnostic Study ◽  
Guided Biopsy ◽  
Iodinated Contrast ◽  
Contrast Enhanced ◽  
Multifocal Breast Cancer ◽  
Conventional Mammography ◽  
Mri Guided

Objective: Contrast Enhanced Spectral Mammography (CESM) breast biopsy has been recently introduced into clinical practice. This short communication describes the technique and potential as an alternative to MRI guided biopsy. Methods and materials: An additional abnormality was detected on a breast MRI examination in a patient with lobular carcinoma. The lesion was occult on conventional mammography, tomosynthesis and ultrasound and required histological diagnosis. Traditionally this would have necessitated a MRI guided breast biopsy, but was performed under CESM guidance. Results: A diagnostic CESM study was performed to ensure the lesion visibility with CESM and then targeted under CESM guidance. A limited diagnostic study, CESM scout and paired images for stereotactic targeting were obtained within a 10 min window following a single injection of iodinated contrast agent. The time from positioning in the biopsy device to releasing compression after biopsy and marker clip placement was 15 min. The biopsy confirmed the presence of multifocal breast cancer. Conclusion: CESM guided breast biopsy is a new technique that can be successfully used as an alternative to MRI guided breast biopsy. Advances in knowledge: CESM guided biopsy can be used to sample breast lesions which remain occult on standard mammography and ultrasound.

Hybrid PET-MRI of the breast: A promising tool for the characterization of breast tumors.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10570-10570
Author(s):  
Katja Pinker-Domenig ◽  
Hubert Bickel ◽  
Wolfgang Bogner ◽  
Heinrich Magometschnigg ◽  
Stephan Gruber ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diagnostic Accuracy ◽  
Standard Dose ◽  
Breast Mri ◽  
Breast Tumors ◽  
Blood Pool ◽  
Imaging Data ◽  
Glucose Levels ◽  
Promising Tool ◽  
Pet Ct

10570 Background: To evaluate if PET-MRI of breast tumors improves staging of breast cancer and obviates unnecessary breast biopsies. Methods: 106 patients with breast tumors detected by mammography or ultrasound and classified as BIRADS 3-5 were included in this IRB approved prospective study. All patients were examined with dedicated 18FDG-PET-CT and 3T multiparametric MRI of the breast. Examinations were scheduled no longer than 7 days apart. MRI protocol included: a diffusion-weighted sequence (DWI), a T2-w sequence and a contrast-enhanced combined high temporal and spatial resolution 3D-T1-w sequence before and after application of a standard dose Gd-DOTA. For PET-CT patients fasted at least 6 h before injection of approx. 300 MBq 18F-FDG based on the patients weight. Scanning was started 45 min after injection. Blood glucose levels were <150 mg/dl. A prone PET dataset over the breasts was acquired using a positioning device allowing the same patient geometry as the breast MRI coil. CT data was used for attenuation correction. Co-registration of imaging data and image fusion were performed. PET-MRI was assessed for lesion morphology and EH-kinetics according to BI-RADS and restricted diffusivity with an ADC threshold 1.25 x10-3mm2/s set as the cut-off for malignancy. Lesions were assed for 18F-FDG–avidity and classified as positive when 18F-FDG-uptake was greater than blood-pool activity. Additionally, nodal status was recorded for each technique and patient. Histopathology was used as the standard of reference. Results: PET-MRI achieved an excellent sensitivity of 100%. Specificity was increased from 68% to 80% as compared to routinely used MRI. Diagnostic accuracy of PET-MRI for diagnosis of breast cancer was 95%. PET-MRI would have obviated unnecessary breast biopsies in 80% of benign breast lesions without missing any cancers. Additionally, PET-MRI increased sensitivity in the detection of lymphnode metastases from 70% to 87% compared to MRI alone. Conclusions: With PET-MRI unnecessary breast biopsies can be obviated without missing any cancers. PET-MRI increases overall diagnostic accuracy in the diagnosis of breast cancer and lymphnode metastases for an accurate staging.

Diversity of non-palpable breast cancer. Timely diagnosis, adequate treatment and prevention

2021 ◽  
pp. 34-40
Author(s):  
N. I. Rozhkova ◽  
I. I. Burdina ◽  
S. B. Zapirova ◽  
P. G. Labazanova ◽  
M. L. Mazo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Mammary Cancer ◽  
Diagnostic Methods ◽  
Breast Diseases ◽  
High Tech ◽  
Adequate Treatment ◽  
X Ray ◽  
Palpable Breast ◽  
Power Radiation

The goal. To show the variety of manifestations of non-palpable breast cancer, which create difficulties in diagnostics and the choice of treatment tactics, to focus on the need to accelerate the introduction of the latest organ-saving treatment and diagnostic technologies and prevention into the system of mammary cancer screening. The main provisions. The epidemiology of cancer, risk factors, positive trends in mammary cancer screening in Russia are presented. A description is given of the diversity of X-ray sonographic and molecular biological manifestations of non-palpable breast cancer based on the results of the analysis of a complex clinical X-ray sonographic pathomorphological and molecular genetic examination of 1,212 patients with clinically latent breast diseases, including 708 patients with non-palpable cancer of various molecular subtypes, manifested by a variety of options – a nodular growth (40.1%), an accumulation of microcalcifications (17.5%), a site of local heavy rearrangement of the structure (31.2%), cancer accompanied by pathological secretion (6.6%), X-ray negative cancer (4.6%). When distributed by stages, 70.3% had T1N0M0, 25% had TisN0M0 and microinvasive cancer. For differential diagnosis, high-tech radiological techniques were used – 3D X-ray and ultrasound tomosynthesis. Effective preoperative diagnostics allowed for adequate organ-saving treatment, including oncoplastic surgery, high-power radiation therapy and modern targeted drug treatment, timely rehabilitation and prevention. Conclusion. Non-palpable breast cancer has many faces. Knowledge of the variants of its manifestations and the use of modern diagnostic methods are necessary for mammary cancer screening, which creates the preconditions for adequate timely organ-saving treatment that preserves the life of patients and its quality.

MRI-Guided Core Biopsy

2018 ◽  
Author(s):  
Lisa A. Mullen
Keyword(s):  
Core Biopsy ◽  
Breast Biopsy ◽  
Breast Mri ◽  
Key Points ◽  
Mri Guided ◽  
Magnetic Resonance Imaging Mri ◽  
Extent Of Disease ◽  
Mass Enhancement ◽  
High Risk Screening

MRI-guided breast biopsy techniques were developed to sample indeterminate and suspicious breast lesions visible only on MRI. Breast MRI performed for high-risk screening, problem solving, or assessment of extent of disease in patients with newly diagnosed breast cancer may demonstrate indeterminate findings, such as enhancing foci, masses or non-mass enhancement. If the lesion is not visible by mammography or ultrasound, and MRI follow-up is not appropriate, then MRI-guided biopsy is indicated. This chapter, appearing in the section on interventions and surgical changes, reviews the key points and procedural protocols and pitfalls for performance of magnetic resonance imaging (MRI)–guided breast core biopsy. Pre-, peri-, and post-procedure clinical management, radiology–pathology correlation, and imaging follow-up are also reviewed.

scholarly journals MRI-Guided Breast Biopsy-Histopathological Verification of Suspicious Breast Lesions Visible on MRI Only

2020 ◽  
Vol 7 (3) ◽  
Author(s):  
Heinze S ◽  
◽  
Rudnicki W ◽  
Popiela T ◽  
Luczynska E ◽  
...  
Keyword(s):  
Breast Biopsy ◽  
Histopathological Examination ◽  
Kinetic Curve ◽  
Breast Mri ◽  
Breast Lesions ◽  
Benign Lesions ◽  
Biopsy Site ◽  
Histopathology Result ◽  
Mri Guided ◽  
Suspicious Lesions

Background: Breast cancer is currently the most frequently diagnosed cancer in women. While the range of modalities enabling suspicious lesions detection is wide, MRI remains the most sensitive one. Therefore, the number of methods verifying the lesions seen only on MRI images grows. The aim of this study is to check the usefulness of MRI guided breast biopsy in clinical use. Methods: The study involved 120 patients who underwent diagnostic MRI before the biopsy that revealed suspicious lesions (BI-RADS 4 and 5). Those lesions had not been seen on initial ultrasonography or mammography. In each case, a marker was placed in the biopsy site and histopathological examination of the obtained samples was performed. Results: The study revealed benign lesions in 86 patients (71.7%). The remaining 34 lesions (28.3%) were determined as malignant, including 19 noninfiltrating (15.8%) and 15 infiltrating lesions (12.5%). Study showed correlation between kinetic curve type and lesion malignancy. Breast type, BPE and enhancement type did not have impact on the histopathology result. Conclusion: Breast MRI-guided biopsy is a reliable way to verify lesions not visible on any other diagnostic imaging methods and therefore should be developed.

Sign in / Sign up

Export Citation Format

Share Document